ACM
ANAB icon

Aster Capital Management’s AnaptysBio ANAB Stock Holding History

Aster Capital Management’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-5,218
Closed -$97K – 834
2026
Q1 		$97K Buy
5,218
+5,093
+4,074% +$274K 0.03% 336
2025
Q4 		$6.06K Buy
+125
New +$4.87K ﹤0.01% 841
2024
Q4 		– Sell
-433
Closed -$14.5K – 1107
2024
Q3 		$14.5K Buy
+433
New +$14.8K ﹤0.01% 733

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Aster Capital Management's ANAB Position: Q2 2026 in Review

Aster Capital Management sold out of AnaptysBio (ANAB) in Q2 2026, closing a stake of 5,218 shares — an estimated $97K sold.

Aster Capital Management first reported a position in ANAB in Q3 2024 and held it in 3 quarters. The position peaked at $97K in Q1 2026. 213 funds tracked by Wall St. Rank hold ANAB as of Q2 2026.

  • Aster Capital Management reported no remaining AnaptysBio position as of Q2 2026 after selling out during the quarter.
  • Aster Capital Management sold 5,218 AnaptysBio shares in Q2 2026, an estimated $97K.
  • Aster Capital Management first reported a position in AnaptysBio in Q3 2024 and held it in 3 quarters.
  • Aster Capital Management's AnaptysBio position peaked at $97K in Q1 2026.
  • 213 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2026.

Based on Aster Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.